GH Research (GHRS) Q2 2026 earnings summary

Executive summary

• Completed two Phase 1 trials for GH001 and received FDA feedback confirming CMC and device plans are Phase 3 ready, targeting pivotal program initiation in 2026.

• Strengthened US and EU patent estate for mebufotenin, with new US patent granted and European patent maintained.

• Published Phase 2a results in postpartum depression and presented additional efficacy data at major scientific meetings.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $362.7 million as of June 30, 2026, up from $280.7 million at year-end 2025, bolstered by $117.5 million in gross proceeds from a Q2 offering.

• Research and development expenses rose to $12.4 million for Q2 2026 from $9.0 million in Q2 2025, reflecting increased clinical and employee costs.

• General and administrative expenses increased to $7.1 million from $5.7 million year-over-year, mainly due to higher professional fees.

• Net loss widened to $15.1 million ($0.23 per share) for Q2 2026, compared to $9.3 million ($0.15 per share) in Q2 2025.

• Total comprehensive loss for Q2 2026 was $17.8 million, compared to $8.9 million in Q2 2025.

Outlook and guidance

• Continues to engage with the FDA on pivotal program design, aiming to initiate Phase 3 in 2026.

• Expects to leverage strong cash position to support ongoing and planned clinical development.